Microdosing GLP-1s began emerging as a trend after Wegovy, an Ozempic competitor, was approved by the FDA for obesity in 2021
This distinction is important: insulin is traditionally measured in international units (IU), whereas peptide-based receptor agonists like retatrutide, semaglutide, and tirzepatide are dosed by weight (milligrams)
Furthermore, agonism of the glucagon receptor increases energy expenditure and promotes fat loss and metabolic activity
Here is what the clinical evidence actually shows: Semaglutide (Wegovy / Ozempic) Semaglutide activates GLP-1 receptors only
evaluated the influence of GLP-1 in 5xFAD mice, where liraglutide restored astrocytic mitochondrial function and prevented neuronal loss
Reports that look like they were created in a word processor, with inconsistent fonts, missing accreditation information, or stock photos of laboratory equipment, are almost certainly fabricated